Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery
Open Access
- 30 June 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 770
- https://doi.org/10.3389/fphar.2020.00770
Abstract
Conventional drug discovery is long and costly, and suffers from high attrition rates, often leaving patients with limited or expensive treatment options. Recognizing the overwhelming need to accelerate this process and increase success, the ATOM consortium was formed by government, industry, and academic partners in October 2017. ATOM applies a team science and open-source approach to foster a paradigm shift in drug discovery. ATOM is developing and validating a precompetitive, preclinical, small molecule drug discovery platform that simultaneously optimizes pharmacokinetics, toxicity, protein-ligand interactions, systems-level models, molecular design, and novel compound generation. To achieve this, the ATOM Modeling Pipeline (AMPL) has been developed to enable advanced and emerging machine learning (ML) approaches to build models from diverse historical drug discovery data. This modular pipeline has been designed to couple with a generative algorithm that optimizes multiple parameters necessary for drug discovery. ATOM's approach is to consider the full pharmacology and therapeutic window of the drug concurrently, through computationally-driven design, thereby reducing the number of molecules that are selected for experimental validation. Here, we discuss the role of collaborative efforts such as consortia and public-private partnerships in accelerating cross disciplinary innovation and the development of open-source tools for drug discovery.Keywords
Funding Information
- National Cancer Institute (HHSN261200800001E)
- U.S. Department of Energy (DE-AC52-07NA27344)
This publication has 41 references indexed in Scilit:
- Curing Consortium FatigueScience Translational Medicine, 2013
- Automated design of ligands to polypharmacological profilesNature, 2012
- Opening Up to Precompetitive CollaborationScience Translational Medicine, 2010
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- Is open innovation the way forward for big pharma?Nature Reviews Drug Discovery, 2010
- Lessons from 60 years of pharmaceutical innovationNature Reviews Drug Discovery, 2009
- The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidatesNature Reviews Drug Discovery, 2007
- Drug DiscoveryPublished by Elsevier BV ,2007
- Can open-source R&D reinvigorate drug research?Nature Reviews Drug Discovery, 2006
- ESOL: Estimating Aqueous Solubility Directly from Molecular StructureJournal of Chemical Information and Computer Sciences, 2004